New Delhi, April 9 -- Gilead Sciences has announced a major strategic move to acquire German clinical-stage biotech firm Tubulis in a deal valued at up to $5 billion, signaling a deeper push into next-generation cancer therapies. The transaction includes an upfront payment of approximately $3.15 billion, along with an additional $1.85 billion tied to future development and regulatory milestones. The deal, expected to close by mid-2026, underscores Gilead's aggressive expansion in oncology and its growing focus on precision-targeted therapies.

At the core of this acquisition is Tubulis' expertise in antibody-drug conjugates (ADCs), a rapidly evolving class of cancer treatments that deliver chemotherapy directly to tumor cells while minimi...